Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07284147
Enrolling by invitation Not applicable

3D Designed Defocus Lenses on Myopia Control in Children and Adolescents

NCT07284147 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Eye Disease Prevention and Treatment Center
Phase
Not applicable
Started
2025-09-01
Last updated
2025-12-16

Condition(s) studied

Myopia Progressing

Investigational drug(s) / intervention(s)

Defocus Lenses

Defocus Lenses: Defocus Lenses on Myopia Control

Study summary

This study aims to evaluate the effectiveness of lenses with 3D Designed Defocus in controlling the progression of myopia in children and adolescents, and to explore the feasibility of effective design, and apply personalized frame lenses for myopia prevention and control.

Eligibility

Sex
ALL
Min age
6 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria: Age: 6-14 years old; After using 1% cyclohexanone hydrochloride eye drops (Saifeijie) for ciliary muscle paralysis, binocular spherical power were within -0.40D\~-4.00D, binocular cylinder power ≤ 1.50D, the anisometropia is ≤ 1.50D, the progression of myopia in the past year is greater than 0.5D, the best corrected far vision is at least 4.8, and the near vision is at least 5.0; Within 3 months, the myopia prevention and control methods such as multifocal glasses, orthokeratology, defocusing flexible glasses, progressive glasses, atropine eye drops, red light and acupuncture and moxibustion treatment were not used; The subject has a willingness to receive treatment and an informed consent form is signed by their legal guardian. Exclusion Criteria: \-

Primary outcome measure(s)

  • Subjective refraction equivalent spherical — 12 months
    Subjective refraction equivalent spherical

Trial sites (1)

FacilityCityRegionStatus
Shanghai Eye Diseases Prevention &Treatment Center/ Shanghai Eye Hospital, School of Medicine, Tongji University Shanghai China

More Shanghai Eye Disease Prevention and Treatment Center trials in China

School-based Myopia Control Trial for Children With Premyopia or Myopia Recruiting
Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses Enrolling by invitation
Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control Active, not recruiting
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia Recruiting
China Children Eye Study Recruiting

Other trials for the same condition

Light Diffraction Glasses in Preventing and Controlling Myopia in Adolescents Active, not recruiting
Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression Active, not recruiting
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07284147 on ClinicalTrials.gov ↗ ← All trials in China